BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.7%

Neg 0% Neu 89.7% Pos 0%

BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.

Comments

No comments yet. Be the first!